Structural properties of group B streptococcal type III polysaccharide conjugate vaccines that influence immunogenicity and efficacy

Infection and Immunity

Volumn 66, Issue 5, 1998, Pages 2186-2192

  Wessels, Michael R ^a,b,d   Paoletti, Lawrence C ^a   Guttormsen, Hilde Kari ^a   Michon, Francis ^c   D'Ambra, Anello J ^c   Kasper, Dennis L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c North American Vaccine Inc   (United States)

^d CHANNING LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROUP B STREPTOCOCCAL TYPE 3 POLYSACCHARIDE CONJUGATE VACCINE; IMMUNOGLOBULIN G; STREPTOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHEMICAL STRUCTURE; COMPETITIVE INHIBITION; DRUG CONJUGATION; DRUG EFFICACY; IMMUNOGENICITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CROSS LINKING; STREPTOCOCCUS AGALACTIAE; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINATION;

EID: 0031922925     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.66.5.2186-2192.1998     Document Type: Article

References (26)

1. Anderson, P. W., M. E. Pichichero, E. C. Stein, S. Porcelli, R. F. Betts, D. M. Connuck, D. Korones, R. A. Insel, J. M. Zahradnik, and R. Eby. 1989. Effect of oligosaccharide chain length, exposed terminal group, and hapten loading on the antibody response of human adults and infants to vaccines of Haemophilus influenzae type b capsular antigen uniterminally coupled to the diphtheria protein crm 197. J. Immunol. 142:2464-2468.
2. Baltimore, R. S., D. L. Kasper, C. J. Baker, and D. K. Goroff. 1977. Antigenic specificity of opsonophagocytic antibodies in rabbit anti-sera to group B streptococci. J. Immunol. 118:673-678.
3. Dick, W. E., and M. Beurret. 1989. Glycoconjugates of bacterial carbohydrate antigens, p. 48-114. In J. M. Cruse and R. E. Lewis, Jr. (ed.), Conjugate vaccines. S. Karger A. G., Basel, Switzerland.
4. Dubois, M., K. A. Gilles, J. K. Hamilton, P. A. Rebers, and F. Smith. 1956. Colorimetric method for the determination of sugars and related substances. Anal. Chcm. 28:350-356.
5. Guttormsen, H.-K., C. J. Baker, M. S. Edwards, L. C. Paoletti, and D. L. Kasper. 1996. Quantitative determination of antibodies to type III group B streptococcal polysaccharide. J. Infect. Dis. 173:142-150.
6. Jennings, H. J., C. Lugowski, and D. L. Kasper. 1981. Conformational aspects critical to the immunospecificity of the type III group B streptococcal polysaccharide. Biochemistry 20:4511-1518.
7. Jennings, H. J., and R. K. Sood. 1994. Synthetic glycoconjugates as human vaccines, p. 325-361. In Y. C. Lee and R. T. Lee (ed.), Neoglycoconjugates: preparation and applications. Academic Press, New York, N.Y.
8. Kabat, E. A., and A. E. Bezer. 1958. The effect of variation in molecular weight on the antigenicity of dextran in man. Arch. Biochem. Biophys. 78:306-318.
9. Kasper, D. L., L. C. Paoletti, M. R. Wessels, H.-K. Guttormsen, V. J. Carey, H. J. Jennings, and C. J. Baker. 1996. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J. Clin. Invest. 98:2308-2314.
10. Laferriere, C. A., R. K. Sood, J.-M. de Muys, F. Michon, and H. J. Jennings. 1997. The synthesis of Streptococcus pneumoniae polysaccharide-tetanus toxoid conjugates and the effect of chain length on immunogenicity. Vaccine 15:179-186.
11. Lagergard, T., J. Shiloach, J. B. Robbins, and R. Schneerson. 1990. Synthesis and immunological properties of conjugates composed of group B Streptococcus type III capsular polysaccharide covalently bound to tetanus toxoid. Infect. Immun. 58:687-694.
12. Larson, E., B. Howlett, and A. Jagendorf. 1986. Artificial reductant enhancement of the Lowry method for protein determination. Anal. Biochem. 155: 243-248.
13. Lees, A., B. L. Nelson, and J. J. Mond. 1996. Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate for use in protein-polysaccharide conjugate vaccines and immunological reagents. Vaccine 14:190-198.
14. Madoff, L., L. Paoletti, J. Tai, and D. Kasper. 1994. Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes. J. Clin. Invest. 94:286-292.
15. Madoff, L. C., J. L. Michel, E. W. Gong, A. K. Rodewald, and D. L. Kasper. 1992. Protection of neonatal mice from group B streptococcal infection by maternal immunization with beta C protein. Infect. Immun. 60:4989-4994.
16. Paoletti, L. C., D. L. Kasper, F. Michon, J. DiFabio, H. J. Jennings, T. D. Tosteson, and M. R. Wessels. 1992. Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates. J. Clin. Invest. 89:203-209.
17. Paoletti, L. C., M. R. Wessels, and D. L. Kasper. 1995. Optimization of group B streptococcal glycoconjugate vaccines, p. 213-217. In R. M. Chanock, F. Brown, H. S. Ginsberg, and E. Norrby (ed.), Vaccines 95. Molecular approaches to the control of infectious diseases. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
18. Paoletti, L. C., M. R. Wessels, F. Michon, J. DiFabio, H. J. Jennings, and D. L. Kasper. 1992. Group B Streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine. Infect. Immun. 60:4009-4014.
19. Peeters, C. C. A. M., A.-M. Tenbergen-Meekes, J. T. Poolman, M. Beurret, B. J. M. Zegers, and G. T. Rijkers. 1991. Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines. Infect. Immun. 59:3504-0510.
20. SAS Institute. 1990. SAS STAT user's guide, version 6, vol. 1. SAS Institute, Cary, N.C.
21. Seppala, I., and O. Makela. 1989. Antigenicity of dextran-protein conjugates in mice. Effect of molecular weight of the carbohydrate and comparison of two modes of coupling. J. Immunol. 143:1259-1264.
22. Wessels, M. R., A. Munoz, and D. L. Kasper. 1987. A model of high-affinity antibody binding to type III group B Streptococcus capsular polysaccharide. Proc. Natl. Acad. Sci. USA 84:9170-9174.
23. Wessels, M. R., L. C. Paoletti, D. L. Kasper, J. L. DiFabio, F. Michon, K. Holme, and H. J. Jennings. 1990. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. J. Clin. Invest. 86:1428-1433.
24. Wessels, M. R., L. C. Paoletti, J. Pinel, and D. L. Kasper. 1995. Immunogenicity and protective activity in animals of a type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J. Infect. Dis. 171:879-884.
25. Wessels, M. R., L. C. Paoletti, A. K. Rodewald, F. Michon, J. DiFabio, H. J. Jennings, and D. L. Kasper. 1993. Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine. Infect. Immun. 61:4760-4766.
26. Wessels, M. R., L. C. Paoletti, H.-K. Guttormsen, F. Michon, A. J. D'Ambra, and D. L. Kasper. Unpublished data.